Evoke Pharma, Inc.

420 Stevens Avenue, Suite 370

Solana Beach, CA 92075

December 26, 2017


Ms. Dorrie Yale

Division of Corporation Finance

Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549



Evoke Pharma, Inc.

Registration Statement on Form S-3

Filed November 14, 2017

File No. 333-221556

Dear Ms. Yale:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf Evoke Pharma, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on Thursday, December 28, 2017, or as soon as practicable thereafter.

If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435. Thank you for your assistance and cooperation in this matter.


Very truly yours,



By:   /s/ Matthew J. D’Onofrio

Matthew J. D’Onofrio

Executive Vice President, Chief

Business Officer and Secretary



Cheston J. Larson, Esq., Latham & Watkins LLP

Matthew T. Bush, Esq., Latham & Watkins LLP